The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer
Open accessAbstract
Purpose: Positive margins dominate clinical outcomes after surgical resections in most solid cancer types, including head and neck squamous cell carcinoma. Unfortunately, surgeons remove cancer in the same manner they have for a century with complete dependence on subjective tissue changes to identify cancer in the operating room. To effect change, we hypothesize that EGFR can be targeted for safe and specific real-time localization of cancer. Experimental Design: A dose escalation study of cetuximab conjugated to IRDye800 was performed in patients (n = 12) undergoing surgical resection of squamous cell carcinoma arising in the head and neck. Safety and pharmacokinetic data were obtained out to 30 days after infusion. Multi-instrument fluorescence imaging was performed in the operating room and in surgical pathology. Results: There were no grade 2 or higher adverse events attributable to cetuximab-IRDye800. Fluorescence imaging with an intraoperative, wide-field device successfully differentiated tumor from normal tissue during resection with an average tumor-to-background ratio of 5.2 in the highest dose range. Optical imaging identified opportunity for more precise identification of tumor during the surgical procedure and during the pathologic analysis of tissues ex vivo. Fluorescence levels positively correlated with EGFR levels. Conclusions: We demonstrate for the first time that commercially available antibodies can be fluorescently labeled and safely administered to humans to identify cancer with sub-millimeter resolution, which has the potential to improve outcomes in clinical oncology. Clin Cancer Res; 21(16); 3658–66. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423
van Dam, G. M., Themelis, G., Crane, L. M. A., Harlaar, N. J., Pleijhuis, R. G., Kelder, W., Sarantopoulos, A., de Jong, J. S., Arts, H. J. G., van der Zee, A. G. J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2472 · Cited by 1,545
Ang, K. K., Berkey, B. A., Tu, X., Zhang, H. Z., Katz, R. L., Hammond, E. H., Fu, K. K., & Milas, L. (2002) · PubMed · Cited by 1,198
Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival
Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., & Tweardy, D. J. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.11.824 · Cited by 1,113
Stummer, W., Novotny, A., Stepp, H., Goetz, C., Bise, K., & Reulen, H. J. (2000) · Journal of Neurosurgery · doi:10.3171/jns.2000.93.6.1003 · Cited by 881
Single-Dose Intravenous Toxicity Study of IRDye 800CW in Sprague-Dawley Rats
Marshall, M. V., Draney, D., Sevick-Muraca, E. M., & Olive, D. M. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0317-x · Cited by 231
Clinical update on cancer: molecular oncology of head and neck cancer
Suh, Y., Amelio, I., Guerrero Urbano, T., & Tavassoli, M. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.548 · Cited by 188
Practical Theoretic Guidance for the Design of Tumor-Targeting Agents
Wittrup, K. D., Thurber, G. M., Schmidt, M. M., & Rhoden, J. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-396962-0.00010-0 · Cited by 171
Li, Y., Rey‐Dios, R., Roberts, D. W., Valdes, P. A., & Cohen‐Gadol, A. (2013) · World Neurosurgery · doi:10.1016/j.wneu.2013.06.014 · Cited by 162
Fluorescence-guided resections of malignant gliomas—An Overview
Stummer, W., Reulen, H. J., Novotny, A., Steppe, H., & Tonn, J. C. (2003) · Local Therapies for Glioma Present Status and Future Developments · doi:10.1007/978-3-7091-6090-9_3 · Cited by 128
Cited by
Near-infrared fluorophores for biomedical imaging
Hong, G., Antaris, A. L., & Dai, H. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0010 · Cited by 2,985
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Near‐Infrared‐II Molecular Dyes for Cancer Imaging and Surgery
Zhu, S., Tian, R., Antaris, A. L., Chen, X., & Dai, H. (2019) · Advanced Materials · doi:10.1002/adma.201900321 · Cited by 972
Beyond the margins: real-time detection of cancer using targeted fluorophores
Zhang, R. R., Schroeder, A. B., Grudzinski, J. J., Rosenthal, E. L., Warram, J. M., Pinchuk, A. N., Eliceiri, K. W., Kuo, J. S., & Weichert, J. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.212 · Cited by 485
Self-citationLatest developments in molecular tracers for fluorescence image-guided cancer surgery
Hernot, S., van Manen, L., Debie, P., Mieog, J. S. D., & Vahrmeijer, A. L. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30317-1 · Cited by 471
Metadata
- Authors
- Rosenthal, E. L., Warram, J. M., de Boer, E., Chung, T. K., Korb, M. L., Brandwein-Gensler, M., Strong, T. V., Schmalbach, C. E., Morlandt, A. B., Agarwal, G., Hartman, Y. E., Carroll, W. R., Richman, J. S., Clemons, L. K., Nabell, L. M., & Zinn, K. R.
- Venue
- Clinical Cancer Research
- Published
- 2015-08-13
- Volume
- 21
- Issue
- 16
- Pages
- 3658-3666
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2106235642
- Cited by
- 469
- References
- 17
- FWCI
- 35.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-3284
- The paper
- Rosenthal, E. L., Warram, J. M., de Boer, E., Chung, T. K., Korb, M. L., Brandwein-Gensler, M., Strong, T. V., Schmalbach, C. E., Morlandt, A. B., Agarwal, G., Hartman, Y. E., Carroll, W. R., Richman, J. S., Clemons, L. K., Nabell, L. M., & Zinn, K. R. (2015). Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-3284
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.